SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Roche Says Gazyva Achieved 36.1% Complete Remission at Two Years

In the Phase III MAJESTY study, Gazyva/Gazyvaro achieved a 36.1% complete remission rate at two years, versus 5.7% with tacrolimus.

Related stories